InnoCare Pharma

Sustainability Report and Carbon Intensity Rankings

Is InnoCare Pharma doing their part?

Their DitchCarbon score is 45

InnoCare Pharma has a DitchCarbon Score of 45 out of 100, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, suggesting there is significant room for improvement in reducing emissions. A higher score would demonstrate a stronger commitment to lowering carbon intensity and enhancing sustainability efforts.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

InnoCare Pharma is part of the research and development sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Unknown

High

Very high

InnoCare Pharma, based in China, operates in a region with a certain carbon intensity rating that influences the company’s environmental impact. The sustainability of InnoCare Pharma’s operations is partially dependent on China’s efforts to manage and reduce its carbon emissions.

Unlock 30+ emissions intelligence data points

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

Unlock 30+ emissions data points on InnoCare Pharma

Get the emissions intelligence you need, no surveys required.

– Historical Scope 1, 2 and 3 emissions

– Coverage of all industries, product level data

– Emissions forecasting, assurances

6.36%

...this company is doing 6.36% worse in emissions than the industry average.

InnoCare Pharma, situated in Beijing, is a prominent player in the research and development sector of the pharmaceutical industry. Founded in CN, the company specializes in the discovery and development of innovative treatments for cancer and autoimmune diseases. InnoCare Pharma offers a range of services from drug discovery to clinical development, aiming to address unmet medical needs with cutting-edge science.

emission intelligence's platform recommendations for InnoCare Pharma

Groupe LDLC should enhance their monitoring and reporting systems to better track progress and identify additional opportunities for reducing emissions from purchased electricity, heat, steam, and cooling, which could potentially lower their emissions by 0.3%.

Bad news, InnoCare Pharma hasn't committed to SBTi goals yet.

InnoCare Pharma has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is still in the process of defining clear, science-based emissions reduction targets to align with global efforts to mitigate climate change.
Not participating

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.

Looking for a specific company?

Search our company directory or contact us for custom data requests.